Profile data is unavailable for this security.
About the company
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. The Company is focused on treating cancer through the design and delivery of ribonucleic acid (RNA) therapeutics based on its TTX nanoparticle platform. The Company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 (PD-L1), and two indication agnostic programs, TTX-RIGA, an RNA-based agonist of the retinoic acid- inducible gene I (RIG-I), targeting activation of innate immunity in the tumor microenvironment; and TTX- CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells. The Company’s pipeline also includes TTX-mRNA, a tumor-type specific mRNA-based platform for the development of cancer vaccines.
- Revenue in USD (TTM)0.00
- Net income in USD-17.06m
- Incorporated2016
- Employees10.00
- LocationTranscode Therapeutics Inc6 Liberty Square, #2382BOSTON 02109United StatesUSA
- Phone+1 (857) 301-6857
- Fax+1 (302) 655-5049
- Websitehttps://www.transcodetherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GT Biopharma Inc | 0.00 | -9.64m | 6.80m | 2.00 | -- | 0.8202 | -- | -- | -7.04 | -7.04 | 0.00 | 3.85 | 0.00 | -- | -- | 0.00 | -64.24 | -205.36 | -90.39 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 63.62 | -- | -- | -- |
| Cyclerion Therapeutics Inc | 0.00 | -10.95m | 6.91m | 1.00 | -- | 0.6423 | -- | -- | -4.38 | 0.2904 | 0.00 | 3.97 | 0.00 | -- | -- | 0.00 | -95.95 | -72.70 | -158.12 | -86.96 | -- | -- | -- | -2,565.62 | -- | -- | 0.00 | -- | -100.00 | -- | 30.98 | -- | -- | -- |
| Actavia Life Sciences Inc | 0.00 | -406.65k | 6.95m | 1.00 | -- | -- | -- | -- | -0.0005 | -0.0005 | 0.00 | -0.0028 | 0.00 | -- | -- | 0.00 | -805.97 | -158.17 | -- | -- | -- | -- | -- | -- | -- | -5.63 | -- | -- | -- | -- | -547.04 | -- | -- | -- |
| Endexx Corp | 4.64m | 6.93m | 7.00m | -- | 1.04 | -- | 1.18 | 1.51 | 0.0133 | 0.0133 | 0.0091 | -0.0255 | 0.6773 | 4.37 | 13.54 | -- | 86.51 | -- | -- | -- | 28.73 | -- | 127.74 | -- | 0.0664 | -- | -- | -- | 228.66 | -- | 28.26 | -- | -- | -- |
| Pulmatrix Inc | 11.68m | -8.85m | 7.20m | 22.00 | -- | 0.3783 | -- | 0.6158 | -2.42 | -2.42 | 3.20 | 5.21 | 0.3517 | -- | 17.84 | 531,090.90 | -26.63 | -46.91 | -30.21 | -58.12 | -- | -- | -75.73 | -238.04 | -- | -- | 0.00 | -- | 20.21 | 116.62 | 25.03 | -- | 104.29 | -- |
| Transcode Therapeutics Inc | 0.00 | -17.06m | 7.28m | 10.00 | -- | 1.39 | -- | -- | -206.36 | -206.36 | 0.00 | 0.7893 | 0.00 | -- | -- | 0.00 | -264.82 | -133.14 | -721.90 | -181.26 | -- | -- | -- | -- | -- | -148.05 | 0.00 | -- | -- | -- | -5.59 | -- | -- | -- |
| Healthy Extracts Inc | 2.56m | -2.76m | 7.32m | -- | -- | 48.27 | -- | 2.86 | -0.9512 | -0.9512 | 0.8819 | 0.0512 | 0.9428 | 0.5035 | 32.10 | -- | -101.47 | -53.78 | -375.65 | -146.65 | 68.46 | 45.68 | -107.63 | -87.53 | 0.1293 | -2.22 | 0.879 | -- | 10.41 | 105.93 | -151.54 | -- | -- | -- |
| Trevena Inc | 3.14m | -40.15m | 7.33m | 23.00 | -- | -- | -- | 2.33 | -2.71 | -2.71 | 0.2107 | -0.7999 | 0.0904 | -- | -- | 136,478.30 | -115.65 | -55.93 | -148.14 | -66.35 | 48.04 | -- | -1,279.01 | -3,134.41 | -- | -15.39 | 1.88 | -- | 847.61 | -11.43 | 24.93 | -- | -24.67 | -- |
| Kazia Therapeutics Ltd (ADR) | 14.85k | -13.47m | 7.43m | 12.00 | -- | 0.7173 | -- | 500.20 | -0.817 | -0.817 | 0.0008 | 0.3478 | 0.0007 | -- | 73.97 | -- | -63.98 | -46.35 | -82.39 | -54.75 | -- | -- | -90,714.45 | -497.17 | -- | -- | 0.1297 | -- | 979.43 | -28.31 | 18.19 | -- | -- | -- |
| Oragenics Inc | 20.63k | -20.26m | 7.48m | 5.00 | -- | 7.25 | -- | 362.71 | -7.98 | -7.98 | 0.0079 | 0.5859 | 0.0026 | -- | -- | 4,126.00 | -258.71 | -97.60 | -312.34 | -106.24 | -- | -- | -98,214.93 | -36,169.75 | -- | -- | 0.0461 | -- | -71.37 | -- | -44.56 | -- | 51.64 | -- |
| Integrated BioPharma, Inc. | 50.57m | -116.00k | 7.52m | 141.00 | -- | 0.3979 | 35.49 | 0.1488 | -0.0041 | -0.0041 | 1.67 | 0.6283 | 1.88 | 4.45 | 10.76 | 358,617.00 | -0.431 | 15.51 | -0.5698 | 27.94 | 7.09 | 12.09 | -0.2294 | 6.44 | 1.02 | -9.00 | 0.001 | -- | -9.91 | 3.00 | -101.35 | -- | -14.03 | -- |
| Cadrenal Therapeutics Inc | -100.00bn | -100.00bn | 7.53m | 3.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Bon Natural Life Ltd | 29.52m | 4.60m | 7.70m | 96.00 | 0.3888 | 0.0642 | 1.40 | 0.2609 | 4.99 | 4.99 | 32.10 | 30.23 | 0.7045 | 15.27 | 5.19 | 307,524.60 | 10.86 | 14.04 | 13.69 | 20.68 | 29.94 | 30.00 | 15.42 | 17.62 | 2.41 | 30.54 | 0.0955 | 0.00 | -1.29 | 22.32 | -26.32 | 83.09 | -6.70 | -- |
| Notable Labs Ltd | 311.00k | -12.39m | 7.71m | 16.00 | -- | 0.6679 | -- | 24.79 | -2.31 | -2.31 | 0.0622 | 1.28 | 0.0142 | -- | -- | 19,437.50 | -56.70 | -52.02 | -74.10 | -62.09 | 37.30 | 60.19 | -3,984.24 | -3,636.93 | -- | -- | 0.0271 | -- | -52.89 | -11.93 | 65.13 | -- | -50.69 | -- |
| National Graphite Corp | 0.00 | -1.97m | 7.72m | 0.00 | -- | -- | -- | -- | -0.0221 | -0.0221 | 0.00 | -0.0193 | 0.00 | -- | -- | -- | -11,014.44 | -212.13 | -- | -6,295.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,432.70 | -- | -- | -- |
| Molecular Templates Inc | 31.76m | -18.40m | 7.77m | 62.00 | -- | 1.08 | -- | 0.2446 | -4.36 | -4.36 | 5.98 | 1.09 | 0.6014 | -- | 19.55 | 512,306.40 | -34.83 | -51.78 | -54.80 | -73.14 | -- | -- | -57.92 | -228.33 | -- | -52.11 | 0.00 | -- | 190.10 | 33.96 | 91.24 | -- | -48.87 | -- |
Data as of Jun 10 2024. Currency figures normalised to Transcode Therapeutics Inc's reporting currency: US Dollar USD
6.35%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Sabby Management LLCas of 31 Mar 2024 | 334.82k | 5.10% |
| Virtu Americas LLCas of 31 Mar 2024 | 55.33k | 0.84% |
| Two Sigma Securities LLCas of 31 Mar 2024 | 21.98k | 0.33% |
| Tower Research Capital LLCas of 31 Mar 2024 | 4.93k | 0.08% |
| Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 5.00 | 0.00% |
| RBC Dominion Securities, Inc.as of 31 Mar 2024 | 1.00 | 0.00% |
| First Personal Financial Services, Inc.as of 31 Mar 2024 | 1.00 | 0.00% |
| Private Capital Management LLC (Colorado)as of 31 Mar 2024 | 0.00 | 0.00% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 0.00 | 0.00% |
| UBS Securities LLCas of 31 Mar 2024 | 0.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
